In a randomised, double-blind placebocontrolled trial, the effects of the administration of oral L-carnitine (2 g/ day) for 28 days were compared in the management of 51 (carnitine group) and 50 (placebo group) patients with suspected acute myocardial infarction. At study entry, the extent of cardiac disease, cardiac enzymes and lipid peroxides were comparable between the groups, although both groups showed an increase in cardiac enzymes and lipid peroxides. At the end of the 28-day treatment period, the mean infarct size assessed by cardiac enzymes showed a significant reduction in the carnitine group compared to placebo. Electrocardiographic assessment of infarct size revealed that the QRS-score was significantly less in the carnitine group compared to placebo (7.4 ± 1.2 vs 10.7 ± 2.0), while serum aspartate transaminase and lipid peroxides showed significant reduction in the carnitine group. Lactate dehydrogenase measured on the sixth or seventh day following infarction showed a smaller rise in the carnitine group compared to placebo. Angina pectoris (17.6 vs 36.0%), New York Heart Association class III and IV heart failure plus left ventricular enlargement (23.4 vs 36.0%) and total arrhythmias (13.7 vs 28.0%) were significantly less in the carnitine group compared to placebo. Total cardiac events including cardiac deaths and nonfatal infarction were 15.6% in the carnitine group vs 26.0% in the placebo group. It is possible that L-carnitine supplementation in patients with suspected acute myocardial infarction may be protective against cardiac necrosis and complications during the first 28 days.
Summary
In a randomised, double-blind placebocontrolled trial, the effects of the administration of oral L-carnitine (2 g/ day) for 28 days were compared in the management of 51 (carnitine group) and 50 (placebo group) patients with suspected acute myocardial infarction. At study entry, the extent of cardiac disease, cardiac enzymes and lipid peroxides were comparable between the groups, although both groups showed an increase in cardiac enzymes and lipid peroxides. At the end of the 28-day treatment period, the mean infarct size assessed by cardiac enzymes showed a significant reduction in the carnitine group compared to placebo. Electrocardiographic assessment of infarct size revealed that the QRS-score was significantly less in the carnitine group compared to placebo (7.4 ± 1.2 vs 10.7 ± 2.0), while serum aspartate transaminase and lipid peroxides showed significant reduction in the carnitine group. Lactate dehydrogenase measured on the sixth or seventh day following infarction showed a smaller rise in the carnitine group compared to placebo. Angina pectoris (17.6 vs 36.0%), New York Heart Association class III and IV heart failure plus left ventricular enlargement (23.4 vs 36.0%) and total arrhythmias (13.7 vs 28.0%) were significantly less in the carnitine group compared to placebo. Total cardiac events including cardiac deaths and nonfatal infarction were 15.6% in the carnitine group vs 26.0% in the placebo group. It is possible that L-carnitine supplementation in patients with suspected acute myocardial infarction may be protective against cardiac necrosis and complications during the first 28 days.
Keywords: carnitine, acute myocardial infarction, cardiac enzyme Myocardial ischaemia is a dynamic process associated with inadequate coronary blood flow.' Carnitine is found in high concentrations in cardiac muscle and it serves several important physiological functions in the heart."3 Hypocarnitinemia and carnitine deficiency in the myocardial tissue has been observed in laboratory animals during experimental ischaemia as well as in patients with heart disease.3`8 There is a reduction in free carnitine in the myocardium during ischaemia whereas there is an increase in acetyl and long-chain acyl carnitine levels.9 However, if the ischaemia is prolonged, total carnitine also decreases. In one study in patients with advanced heart disease,4 myocardial free carnitine was only 60% of that of control subjects. Carnitine deficiency in the myocardium has also been described in patients dying of acute myocardial infarction.3 The deficiency was more marked in the infarcted portion of the myocardium than in healthy myocardium.3 In another study,7 a myocardial free carnitine below 6.5 nmol/g noncollagenous protein was associated with a marked decline in ejection fraction compared to controls with a mean free carnitine level of 9.7 nmol/g. Recent studies show that even in the presence of normal carnitine, long chain acylcamitine levels are significantly elevated during myocardial ischaemia which may have an adverse effect upon myocardial function.'0"'1 The significant relationship between the concentrations of carnitine and its derivatives and myocardial function and the reduction in free camitine during ischaemia, form the basis for the hypothesis that exogenous carnitine supplementation may minimise long-chain acylcarnitine accumulation and cardiac necrosis, as well as improving cardiac metabolism and function in patients with ischaemic heart disease."'5 Carnitine administration has been reported to be beneficial in patients with angina,'2"13 chronic myocardial ischaemia, and recent myocardial infarction.'4 In this Indian study of infarct survival we report, possibly for the first time, the effect of L-carnitine administration on cardiac enzymes and lipid peroxides in patients with suspected acute myocardial infarction in a randomised trial.
Patients and methods
The study was had an acute infarction with onset of symptoms in the preceding 24 hours. No electrocardiographic inclusion criteria were specified. There were no specific exclusion criteria, although patients who were unable or unwilling to give verbal consent (n = 4), and those admitted more than 24 hours after the onset of symptoms (n = 7), were excluded.
Acute myocardial infarction was diagnosed'6 in the presence of symmetrical ST-segment elevation of > 1 mm from baseline in limb leads or of > 2 mm in chest leads or T-wave inversions with or without Q waves in a 12-lead electrocardiogram in association with an increase in creatine kinase and serum aspartate transaminase of at least twice the upper limit of normal on serial examinations (n = 81). Suspected or possible acute myocardial infarction was also diagnosed on the basis of a convincing history ofcardiac chest pain accompanied by an increase in cardiac enzymes of less than twice the upper limit of normal and electrocardiographic abnormalities that were suggestive of acute myocardial infarction (n = 10). Unstable angina was diagnosed in the presence ofcardiac chest pain for > 30 minutes without a significant increase in enzymes or diagnostic electrocardiographic changes or a combination of these (n = 6). Noncardiac chest pain was diagnosed in the absence ofall ofthe above manifestations of coronary artery disease (n = 4). 28 -day survival was also obtained from hospital and health authority records. Total cardiac events included nonfatal myocardial infarction (diagnostic criteria mentioned above) and cardiac deaths. Counselling for routine physical activity, mental stress, and maintenance of regular bowel movements was provided in both groups if required.
TREATMENTS

SIZE OF INFARCTION
The size of the acute myocardial infarction was assessed on the basis of electrocardiographic changes and cardiac enzyme activity. A blood sample for creatine kinase and its muscle brain (MB) fraction was drawn every four hours within the first 24 hours, every six hours on the second day and once daily for the last eight days. Infarct size was considered as the product of a proportionality constant K, body weight Electrocardiographic assessment of infarct size was done with the help of the 12-lead electrocardiograms of patients before therapy, then on the third, seventh and tenth days of treatment. Electrocardiograms showing bundle branch block and paced rhythm were not analysed. Based on a method derived from Marako, the summated Q-wave depths and R-wave heights in leads VI to V6 for anterior infarction were compared between the two groups.
LABORATORY DATA A venous blood sample was drawn immediately after admission to hospital and analysed for blood counts, haemoglobin, urea, glucose, cardiac enzyme activity and carnitine.'8 Lactate dehydrogenase and aspartate transaminase were analysed daily during the first week of hospitalisation. All analyses were performed by technicians unaware of the treatment groups of the patients.
A spectrophotometric method'7 for quantitative assay of plasma lipid peroxides free of interference from sialic acid was used and lipid peroxidation was determined by the thiobarbituric acid reactivity of malonyldialdehyde. Butylated hydroxytoluene and 30% trichloroacetic acid were added to plasma to develop the reaction. The thiobarbituric acid was dissolved in sodium sulphate solution and the liberation of lipid peroxide and colour reaction were measured simultaneously. Absorbance was read by UV-visible spectrophotometry.
STATISTICAL ANALYSES
Data were analysed on the basis ofintention-totreat. In the all-outcome analysis, the last available clinical or laboratory data were incorporated for patients who were lost to follow-up or died. Only p-values <0.05 in two-tailed Table 2 shows that myocardial infarct size was significantly less in the carnitine group compared to the placebo group as revealed by the levels of creatine kinase and creatine kinase-MB. Electrocardiographic assessment of infarct size in the carnitine group also showed a significant reduction compared to the placebo group. The QRS scores during the first 10 days of follow-up were significantly lower in the carnitine group than in the placebo group (table  2) .
LABORATORY DATA At entry to study, cardiac enzymes and lipid peroxides (thiobarbituric acid reactive substances) were comparable between the two groups. An increase in lipid peroxide is the indicator of cell membrane damage due to free radical stress in acute myocardial infarction. After treatment, the carnitine group showed a greater reduction in aspartate transaminase and lipid peroxides and a smaller rise in lactate dehydrogenase compared to the placebo group (table 3) .
COMPLICATIONS AND CARDIAC EVENTS
Angina pectoris, the total number of cases with poor left ventricular function (class III and IV heart failure plus left ventricular enlargement), and total arrhythmias were significantly less in the carnitine group compared to the placebo group. Total cardiac events including nonfatal infarction and cardiac deaths were significantly fewer in the carnitine group compared to placebo during the 28 days of follow-up (table  4) .
Discussion
In acute myocardial infarction, the ischaemic damage and metabolic reactions are so rapid that benefits oftreatment are difficult to achieve if the treatment is not given imnmediately after infarction.'9 The majority of our patients were given carnitine within 10 hours of the onset of symptoms. The results showed that carnitine (table 2) . Plasma levels of thiobarbituric acid reactive substances which arise due to degradation ofcell polyunsaturated fatty'7 acids also showed a greater reduction with carnitine compared to placebo. Since an increase in these subgroups in patients with acute myocardial infarction may be the result of cardiac damage due to over production of free radicals,202' the possibility exists that carnitine administration might inhibit free radical injury to myocardium. However, more studies would be necessary to confirm this hypothesis. Apart from the reduction in infarct size indicated by cardiac enzyme activity, electrocardiographic infarct size showed a significant decline in the carnitine group compared to placebo (table 2). In one study,'5 the effect of orally administered L-camitine (40 mg/kg daily) on the release and maximum serum concentrations of creatine kinase-MB during the first 48-72 hours was examined in 22 patients with acute myocardial infarction. Compared with untreated controls, L-carnitine supplementation was associated with a decreased release ofcreatine kinase-MB (465 vs 520 mg/l) and a lower maximum value (165 vs 205 mg/l). The finding that free L-carnitine concentrations in myocardial tissue from infarcted areas of patients dying of acute myocardial infarction was much lower than that from heart tissues of patients dying due to other causes, suggest that L-carnitine may have a role in limiting necrosis.3 There is some more evidence from open clinical trials2224 that treatment with L-carnitine caused a reduction in the area of necrosis in patients with acute myocardial infarction. In controlled trials,24 single intravenous doses of L-carnitine (40-140 mg/ kg) reduced the production of lactate in the myocardium compared to placebo-treated control subjects. In another study25 in 40 patients undergoing aorto-coronary by-pass surgery, pretreatment with L-carnitine (1 g/day) for two days and 0.5 g intravenously prior to surgery was associated with a reduction in lactate levels in the myocardium with a significant increase in levels of adenosine triphosphate (ATP) without such changes in the control group.
The exact mechanism of action by which L-carnitine modulates myocardial metabolism in patients with ischaemic heart disease is not known. It is possible that L-carnitine prevents inhibition of glucose metabolism, preserves fatty acid metabolism and removes toxic longchain fatty acid metabolites from the myocardial tissue.'~4 It is not known whether Lcarnitine can scavenge free radicals generated due to the presence of a free hydroxyl group in its chemical structure.'2 It seems that the availability of free carnitine stimulates betaoxidation, thereby reducing intramitrochondrial acyl-coenzyme A and increasing ATP production.'~4 The decrease in intramito- A/coenzyme A ratio.2 During ischaemia, oxidative utilisation of pyruvate helps in maintaining ATP26 which may reduce muscle necrosis. Similarly, angina may be reduced because intracellular energetics are improved by the drug which may decrease the oxygen requirement of the cell. Since carnitine has no effect on thrombosis, it should not be compared with thrombolytics, although both drugs reduce infarction size. The improvement in myocardial necrosis in acute myocardial infarction patients with carnitine supplementation was associated with a significant decline in angina pectoris and total cardiac arrhythmias and a reduction in class III and IV heart failure and left ventricular enlargement. Although total cardiac mortality did not show a significant reduction in the carnitine group, total cardiac events were significantly fewer in the carnitine group compared to the placebo group ( 
